Moreover, a highly selective MET tyrosine kinase inhibitor, savolitinib, was evaluated for its safety, pharmacokinetics, and anti-tumor activity in a first-in-human phase I trial in patients with advanced solid tumors (Gan et al., 2019) and was tested in a biomarker-based phase II trial of patients with advanced papillary renal cell carcinoma (PRCC; Choueiri et al., 2017). The gene discussed is MET; the disease is neoplasm.